Mineralys Therapeutics Inc MLYS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $12.37
- Day Range
- $12.04–12.46
- 52-Week Range
- $5.89–17.63
- Bid/Ask
- $12.00 / $12.08
- Market Cap
- $597.56 Mil
- Volume/Avg
- 15,788 / 171,612
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 28
- Website
- https://mineralystx.com
Comparables
Valuation
|
Metric
|
MLYS
|
PLRX
|
EWTX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.11 | 1.53 | 3.77 |
Price/Sales | — | 449.31 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
MLYS
PLRX
EWTX
Financial Strength
|
Metric
|
MLYS
|
PLRX
|
EWTX
|
|---|---|---|---|
Quick Ratio | 22.57 | 17.43 | 18.98 |
Current Ratio | 23.76 | 17.72 | 19.50 |
Interest Coverage | — | −145.34 | — |
Quick Ratio
MLYS
PLRX
EWTX
Profitability
|
Metric
|
MLYS
|
PLRX
|
EWTX
|
|---|---|---|---|
Return on Assets (Normalized) | −26.92% | −22.68% | −24.36% |
Return on Equity (Normalized) | −32.33% | −24.50% | −25.87% |
Return on Invested Capital (Normalized) | −38.50% | −28.46% | −29.82% |
Return on Assets
MLYS
PLRX
EWTX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Kpctsvbrz | Rvrtg | $566.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Llzlpgm | Kqrktg | $102.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Yytxrmrhl | Rgrvfy | $98.3 Bil | |
MRNA
| Moderna Inc | Qjghfrbsh | Gnzw | $42.7 Bil | |
ARGX
| argenx SE ADR | Lyhkwkj | Hpnp | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Dkpfwkq | Ypq | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Bqjwzyhb | Jnthzdy | $18.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xkxbtggz | Dwdvxt | $15.6 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dyrpnjhqj | Zdhcfq | $12.7 Bil | |
INCY
| Incyte Corp | Xcgpsgwr | Grdqn | $11.8 Bil |